Synflorix Dosage/Direction for Use

Official recommendations should be taken into account when immunising with Synflorix.
Infants from 2 months to 6 months of age: Three-dose primary series: The recommended immunization series to ensure optimal protection consists of four doses, each of 0.5 mL. The primary infant series consists of three doses with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses. A booster dose is recommended at least 6 months after the last primary dose (see Pharmacology: Pharmacodynamics under Actions).
Two-dose primary series: Alternatively, when Synflorix is given as part of a routine infant immunization programme, a series consisting of three doses, each of 0.5 mL may be given. The first dose may be administered from the age of 2 months, with a second dose 2 months later. A booster dose is recommended at least 6 months after the last primary dose (see Pharmacology: Pharmacodynamics under Actions).
Preterm infants born after at least 27 weeks of gestational age: The recommended immunization series consists of four doses, each of 0.5 mL. The primary infant series consists of three doses with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses. A booster dose is recommended at least 6 months after the last primary dose (see Pharmacology: Pharmacodynamics under Actions).
Previously unvaccinated older infants and children: 7-11 months of age: 2 doses of 0.5 mL with an interval of at least 1 month between doses. A third dose is recommended in the second year of life with an interval of at least 2 months.
12 months - 5 years of age: 2 doses of 0.5 mL with an interval of at least 2 months between doses.
Special populations: The safety and immunogenicity of Synflorix in children with underlying immunocompromising conditions predisposed them to invasive pneumococcal diseases (such SCD or HIV infection or splenic dysfunction) have been studied in children below 2 years of age. Limited data are available for children with asplenia or splenic dysfunction ages 2 to 5 years.
Synflorix may be given according to the previously mentioned schedules, except that a 3-dose schedule should be given as primary vaccination in infants starting vaccination from 2 months to 6 months of age (see Pharmacology: Pharmacodynamics under Actions and Precautions).
It is recommended that subjects who receive a first dose of Synflorix complete the full vaccination course with Synflorix.
The vaccine should be given by intramuscular injection. The preferred sites are anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in children.